On August 11, 2022, GeneCradle successfully passed the ISO9001 quality management system certification and obtained the certification certificate. The scope of this certification covers the preclinical research of genetic drug technology.
GeneCradle Quality Policy
GeneCradle takes "originating from demand, courageous innovation, dedicated to design, strict verification, sophisticated manufacturing, continuous improvement, and benefit to patients" as its quality management policy, which comprehensively and meticulously explains the company's overall quality purpose and direction, which is the foundation of the company's quality management. From the R&D project establishment of gene therapy drugs to R&D technology innovation, and then to drug design, verification, manufacturing, and listing to meet the needs of patients, the company has formulated standards and requirements for management and execution in all aspects.
The successful passing of this quality management system certification also prompted all GeneCradle staff to require their daily work with stricter quality goals, and always urged the company to continuously improve its quality management level, conscientiously do every step in the process of gene therapy drug R&D and production, adhere to the concept of "no small matter in making medicine, using medicine is like using soldiers", promote rare disease gene therapy drugs from R&D to clinical practice, and provide patients with better gene drug options.
About GeneCradle
Beijing GeneCradle Technology Co., Ltd. is a biotechnology platform company focusing on the innovative research and development of gene therapy drugs. It focuses on the research and development of gene therapy products in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases mediated by AAV vector delivery technology. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, and is committed to turning "incurable" into "once and for all" cures, benefiting patients and their families. Through the research and development and clinical application of rare disease gene drugs, we have a deeper understanding of life and health, and transition to the treatment and rehabilitation of chronic diseases and other major diseases.